Biotech Exit: Million Arcellx Sparks Investor Reassessment
A notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
Discover which Aristocrats ETF delivers the best value by fee and why cost matters for long-term returns. Learn quick tips to compare expense ratios and pick the right fund.
25,968 articlesA notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
As Netflix stumbles, investors wonder if Disney down 2026 offers a rare contrarian opportunity. This article digs int...
Philip Morris International and British American Tobacco report 2025 results, revealing divergent paths in smoke-free...
Investors are watching Meta Platforms for a potential stock split. This guide explains how splits work, what they mea...
Abbott Laboratories and Pfizer both delivered solid Q1 2026 numbers, yet the market sentiment diverged. Abbott slumpe...
Think HSAs are only for medical bills? This guide reveals how to leverage an HSA as a stealth retirement account—comb...
Chevron sits at the heart of today’s energy debate: steady production, looming supply gaps, and the question every in...
Bitcoin's recent surge has sparked talk of a new bull leg. Yet Wintermute's warning — wintermute cautions 'relief ral...
A major fund recently sold its entire NIO position for about $79.8 million. This article breaks down what happened, w...
A recent SEC filing shows Brightlight Capital trimmed its Hilton stake by 79,500 shares, reducing the position's valu...
A three-way market story unfolds: the Dow climbs, Nasdaq retreats, and SpaceX headlines keep investors guessing. Here...
Looking for a meaningful tech stock investment with a modest starting stake? Here is a practical case for Uber as the...